RARE – Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.RARE
$31.35Name : Ultragenyx Pharmaceutical Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,020,769,024.00
EPSttm : -5.48
Ultragenyx Pharmaceutical Inc.
$31.35
5.40%$1.60Float Short %
8.87
Margin Of Safety %
Put/Call OI Ratio
0.33
EPS Next Q Diff
0.06
EPS Last/This Y
1.23
EPS This/Next Y
1.35
Price
29.73
Target Price
86.05
Analyst Recom
1.19
Performance Q
-28.23
Relative Volume
0.68
Beta
0.29
Ticker: RARE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | RARE | 31.52 | 0.44 | 0.17 | 49676 |
| 2025-09-09 | RARE | 31.51 | 0.44 | 0.23 | 50254 |
| 2025-09-10 | RARE | 31.3 | 0.44 | 0.12 | 50313 |
| 2025-09-11 | RARE | 31.31 | 0.43 | 0.70 | 50639 |
| 2025-09-12 | RARE | 30.29 | 0.43 | 0.31 | 50664 |
| 2025-09-15 | RARE | 29.01 | 0.43 | 1.28 | 50681 |
| 2025-09-16 | RARE | 29.5 | 0.43 | 0.33 | 50618 |
| 2025-09-17 | RARE | 28.71 | 0.43031860806689 | 0.31518624641834 | 50639 |
| 2025-09-18 | RARE | 29.03 | 0.43 | 0.73 | 50659 |
| 2025-09-19 | RARE | 28.11 | 0.43 | 0.39 | 50749 |
| 2025-09-22 | RARE | 29.44 | 0.34 | 0.06 | 45370 |
| 2025-09-23 | RARE | 28.38 | 0.34 | 0.13 | 45700 |
| 2025-09-24 | RARE | 28.76 | 0.32 | 0.03 | 48489 |
| 2025-09-25 | RARE | 27.81 | 0.34 | 0.23 | 47675 |
| 2025-09-26 | RARE | 29.08 | 0.34 | 0.35 | 47591 |
| 2025-09-29 | RARE | 30.33 | 0.34 | 0.12 | 48119 |
| 2025-09-30 | RARE | 30.06 | 0.34 | 1.36 | 48028 |
| 2025-10-01 | RARE | 30 | 0.35 | 0.01 | 48251 |
| 2025-10-02 | RARE | 30.9 | 0.34 | 0.20 | 49311 |
| 2025-10-03 | RARE | 31.2 | 0.33 | 0.06 | 49968 |
| 2025-10-06 | RARE | 30.18 | 0.32 | 0.77 | 51361 |
| 2025-10-07 | RARE | 29.75 | 0.33 | 4.99 | 51527 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | RARE | 31.51 | 13.6 | -85.6 | -5.06 |
| 2025-09-09 | RARE | 31.50 | 13.6 | -91.4 | -5.06 |
| 2025-09-10 | RARE | 31.31 | 13.6 | -88.0 | -5.06 |
| 2025-09-11 | RARE | 31.23 | 13.6 | -90.8 | -5.06 |
| 2025-09-12 | RARE | 30.29 | 13.6 | -72.2 | -5.06 |
| 2025-09-15 | RARE | 29.01 | 13.6 | -63.7 | -5.06 |
| 2025-09-16 | RARE | 29.48 | 13.6 | -103.0 | -5.06 |
| 2025-09-17 | RARE | 28.71 | 13.6 | -74.7 | -5.06 |
| 2025-09-18 | RARE | 29.09 | 13.6 | -100.9 | -5.06 |
| 2025-09-19 | RARE | 28.12 | 13.6 | -69.5 | -5.06 |
| 2025-09-22 | RARE | 29.47 | 13.6 | -124.2 | -5.06 |
| 2025-09-23 | RARE | 28.38 | 13.6 | -67.5 | -5.06 |
| 2025-09-24 | RARE | 28.77 | 13.6 | -100.7 | -5.06 |
| 2025-09-25 | RARE | 27.82 | 13.6 | -70.1 | -5.06 |
| 2025-09-26 | RARE | 29.08 | 13.6 | -122.7 | -5.06 |
| 2025-09-29 | RARE | 30.35 | 13.6 | -121.3 | -5.06 |
| 2025-09-30 | RARE | 30.07 | 13.6 | -85.6 | -5.06 |
| 2025-10-01 | RARE | 30.00 | 13.6 | -90.3 | -5.06 |
| 2025-10-02 | RARE | 30.89 | 13.6 | -111.9 | -5.06 |
| 2025-10-03 | RARE | 31.21 | 13.6 | -98.6 | -5.06 |
| 2025-10-06 | RARE | 30.19 | 13.6 | -76.8 | -5.06 |
| 2025-10-07 | RARE | 29.73 | 13.6 | -81.9 | -5.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | RARE | -0.07 | 4.79 | 9.38 |
| 2025-09-09 | RARE | -0.07 | 4.79 | 9.38 |
| 2025-09-10 | RARE | -0.07 | 4.79 | 9.38 |
| 2025-09-11 | RARE | -0.05 | 4.79 | 9.28 |
| 2025-09-12 | RARE | -0.08 | 4.79 | 9.28 |
| 2025-09-15 | RARE | -0.08 | 4.79 | 9.28 |
| 2025-09-16 | RARE | -0.08 | 4.79 | 9.28 |
| 2025-09-17 | RARE | -0.08 | 4.79 | 9.28 |
| 2025-09-18 | RARE | -0.08 | 4.79 | 9.28 |
| 2025-09-19 | RARE | -0.08 | 4.79 | 9.28 |
| 2025-09-22 | RARE | -0.09 | 4.78 | 9.28 |
| 2025-09-23 | RARE | -0.09 | 4.78 | 9.28 |
| 2025-09-24 | RARE | -0.09 | 4.78 | 9.28 |
| 2025-09-25 | RARE | -0.09 | 4.78 | 8.87 |
| 2025-09-26 | RARE | -0.09 | 4.78 | 8.87 |
| 2025-09-29 | RARE | -0.09 | 4.88 | 8.87 |
| 2025-09-30 | RARE | -0.09 | 4.88 | 8.87 |
| 2025-10-01 | RARE | -0.09 | 4.88 | 8.87 |
| 2025-10-02 | RARE | -0.09 | 4.88 | 8.87 |
| 2025-10-03 | RARE | -0.09 | 4.88 | 8.87 |
| 2025-10-06 | RARE | -0.09 | 4.90 | 8.87 |
| 2025-10-07 | RARE | -0.09 | 4.90 | 8.87 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.17
Avg. EPS Est. Current Quarter
-1.21
Avg. EPS Est. Next Quarter
-1.11
Insider Transactions
-0.09
Institutional Transactions
4.9
Beta
0.29
Average Sales Estimate Current Quarter
167
Average Sales Estimate Next Quarter
183
Fair Value
Quality Score
37
Growth Score
51
Sentiment Score
66
Actual DrawDown %
83.5
Max Drawdown 5-Year %
-85.2
Target Price
86.05
P/E
Forward P/E
PEG
P/S
4.7
P/B
18.91
P/Free Cash Flow
EPS
-5.53
Average EPS Est. Cur. Y
-5.06
EPS Next Y. (Est.)
-3.71
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-87.34
Relative Volume
0.68
Return on Equity vs Sector %
-377.5
Return on Equity vs Industry %
-363.8
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-81.9
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1294
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading